UBS Maintains Neutral on BioXcel Therapeutics, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow maintains a Neutral rating on BioXcel Therapeutics (NASDAQ:BTAI) but lowers the price target from $3.5 to $1.
August 09, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Colin Bristow maintains a Neutral rating on BioXcel Therapeutics but significantly lowers the price target from $3.5 to $1.
The significant reduction in the price target from $3.5 to $1 by UBS suggests a negative outlook on BioXcel Therapeutics' future performance, likely leading to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100